A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis

Marlyn J. Mayo, Paul J. Pockros, David Jones, Christopher L. Bowlus, Cynthia Levy, Imran Patanwala, Bruce Bacon, Velimir Luketic, Raj Vuppalanchi, Sharon Medendorp, Alejandro Dorenbaum, Ciara Kennedy, Patricia Novak, Joan Gu, George Apostol, Gideon M. Hirschfield – 1 February 2019 – Primary biliary cholangitis (PBC) is typically associated with elevated serum bile acid levels and pruritus, but pruritus is often refractory to treatment with existing therapies.

Prognostic Role of Ammonia in Patients With Cirrhosis

Shalimar, Mohammed Faisal Sheikh, Rajeshwar P. Mookerjee, Banwari Agarwal, Subrat Kumar Acharya, Rajiv Jalan – 31 January 2019 – Ammonia is thought to be central to the pathogenesis of hepatic encephalopathy (HE), but its prognostic role in patients with cirrhosis and acute decompensation is unknown. The aims of this study were to determine the relationship between ammonia levels and severity of HE and its association with organ dysfunction and short‐term mortality. We identified 498 patients from two institutions as part of prospective observational studies in patients with cirrhosis.

High‐Quality Diets Are Associated With Reduced Risk of Hepatocellular Carcinoma and Chronic Liver Disease: The Multiethnic Cohort

David Bogumil, Song‐Yi Park, Loïc Le Marchand, Christopher A. Haiman, Lynne R. Wilkens, Carol J. Boushey, Veronica Wendy Setiawan – 31 January 2019 – Hepatocellular carcinoma (HCC) and chronic liver disease (CLD) are major sources of morbidity and mortality globally. Both HCC incidence and CLD mortality are known to vary by race. There is limited research on the association between dietary measures and these outcomes in a diverse population.

Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)‐Viremic Donors Into HCV‐Negative Recipients: Outcomes Following Liver Transplant of HCV‐Viremic Donors

Thomas G. Cotter, Sonali Paul, Burhaneddin Sandıkçı, Thomas Couri, Adam S. Bodzin, Ester C. Little, Vinay Sundaram, Michael Charlton – 31 January 2019 – Direct‐acting antiviral (DAA) therapy has altered the frequency and outcome of liver transplantation (LT) for hepatitis C virus (HCV). The high efficacy and tolerability of DAA therapy has also created a rationale for utilizing HCV‐viremic (HCV‐RNA–positive) donors, including into HCV‐negative recipients.

Subscribe to